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Abstract
Purpose To characterize the cardiovascular proﬁle of
sorafenib, a multitargeted kinase inhibitor, in patients with
advanced cancer.
Methods Fifty-three patients with advanced cancer
received oral sorafenib 400 mg bid in continuous 28-day
cycles in this open-label study. Left ventricular ejection
fraction (LVEF) was evaluated using multigated acquisi-
tion scanning at baseline and after 2 and 4 cycles of
sorafenib. QT/QTc interval on the electrocardiograph
(ECG) was measured in triplicate with a Holter 12-lead
ECG at baseline and after 1 cycle of sorafenib. Heart rate
(HR) and blood pressure (BP) were obtained in duplicate at
baseline and after 1 and 4 cycles of sorafenib. Plasma
pharmacokinetic data were obtained for sorafenib and its 3
main metabolites after 1 and 4 cycles of sorafenib.
Results LVEF (SD) mean change from baseline was -0.8
(±8.6) LVEF(%) after 2 cycles (n = 31) and -1.2 (±7.8)
LVEF(%) after 4 cycles of sorafenib (n = 24). The
QT/QTc mean changes from baseline observed at maxi-
mum sorafenib concentrations (tmax) after 1 cycle (n = 31)
were small (QTcB: 4.2 ms; QTcF: 9.0 ms). Mean changes
observed after 1 cycle in BP (n = 31) and HR (n = 30) at
maximum sorafenib concentrations (tmax) were moderate
(up to 11.7 mm Hg and -6.6 bpm, respectively). No cor-
relation was found between the AUC and Cmax of sorafenib
and its main metabolites and any cardiovascular
parameters.
Conclusions The effects of sorafenib on changes in
QT/QTc interval on the ECG, LVEF, BP, and HR were
modest and unlikely to be of clinical signiﬁcance in the
setting of advanced cancer treatment.
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Introduction
Small molecule inhibitors of the vascular endothelial
growth factor receptor (VEGFR) that target tumor angio-
genesis are accepted treatments for several advanced can-
cers. Recent studies have suggested that tyrosine kinase
inhibitors (TKI) with molecular targets involved in angio-
genesis may be associated with cardiac adverse events
(CAEs), such as a decline in left ventricular ejection
fraction (LVEF) and the development of congestive heart
failure (CHF), myocardial infarction (MI), QT/QTc inter-
val prolongation, and hypertension [1–10]. Sorafenib, an
antiangiogenic multitargeted kinase inhibitor, is indicated
for the treatment of patients with advanced renal cell
carcinoma (RCC) and patients with unresectable hepato-
cellular carcinoma (HCC). Sorafenib inhibits B-Raf,
VEGFR-2 and VEGFR-3, platelet-derived growth factor
receptor (PDGFR)-b, stem cell factor receptor c-KIT, RET,
and FLT-3 [11].
The inhibition of normal signaling pathways in cardio-
myocytes that depend upon serine/threonine Raf kinases or
the receptor tyrosine VEGFR and PDGFR kinases by
sorafenib raises the possibility of cardiotoxicity [12–16].
However, reports of cardiotoxicity during treatment with
sorafenib in two large randomized, placebo-controlled,
double-blind, international phase III trials have been
infrequent. In randomized studies for RCC [17] and HCC
[18], the incidence of treatment-emergent cardiac ische-
mia/infarction AEs based on the ﬁnal safety analysis was
2.9 and 2.7% in patients treated with sorafenib compared
with 0.4 and 1.3% in the placebo groups in these trials,
respectively. In the RCC phase III study, the safety analysis
was performed comparing the randomized treatment
groups (sorafenib versus placebo), as well as evaluating
patients who were initially randomized to placebo and then
given the option of crossing over to sorafenib based on
positive ﬁndings from an independently assessed formal
analysis of progression-free survival (PFS), which showed
a signiﬁcant doubling in median PFS with sorafenib over
that with placebo. In a safety analysis update performed on
a database 16 months post-crossover, 4.9% of patients
randomized to the sorafenib group reported cardiac ische-
mia/infarction AEs [19]. Three patients (1.4%) who cros-
sed over from the placebo group to sorafenib also reported
cardiac ischemia/infarction AEs while on sorafenib in this
analysis. It is noteworthy that patients with coronary artery
disease (CAD) or recent MI were excluded from these
studies. A recent retrospective analysis of cardiovascular
safety data from 18 studies of sorafenib monotherapy
across multiple tumor types, however, reported a low
overall rate of CHF and MI (1.6 and 1.5% of all patients,
respectively), with treatment-emergent hypertension being
reported in 18.6% of patients [20].
Although treatment with sorafenib does not appear to
lead to cardiotoxicity, the full incidence and severity of
CAEs that may occur with its administration are unknown
because previous clinical trials with sorafenib have not
speciﬁcally included cardiac end points. All clinical studies
of sorafenib have recorded CAEs as part of the general
safety monitoring for toxicity; the identiﬁcation of CAEs
was predominantly based on the occurrence of clinical
symptoms. None of the trials were speciﬁcally designed to
evaluate the full cardiovascular proﬁle of sorafenib. The
objective of this study was to further evaluate the effect of
continuous sorafenib monotherapy on cardiovascular safety
parameters, such as LVEF, QT/QTc interval, blood pres-
sure (BP), and heart rate (HR) in cancer patients, and
correlate any CAEs with sorafenib pharmacokinetics (PK)
to enhance understanding of the cardiovascular proﬁle of
sorafenib.
Materials and methods
This open-label study of sorafenib enrolled patients with
histologically or cytologically conﬁrmed advanced solid
tumors (excluding colorectal cancer) or lymphomas.
Patients had to have a life expectancy of at least 12 weeks;
adequate bone marrow, liver, and renal function; and an
Eastern Cooperative Oncology Group Performance Status
(ECOG PS) of 0 or 1. Study eligibility criteria included
baseline LVEF C45%, systolic BP B170 mm Hg, diastolic
BP B100 mm Hg, and a QTc\500 ms. Therapy to control
hypertension was allowed. Exclusion criteria included
previous CHF [ New York Heart Association (NYHA)
Class 2, cardiac arrhythmias requiring antiarrhythmic
therapy other than beta blockers or digoxin, uncontrolled
hypertension, history of HIV infection or chronic hepatitis
B or C, systemic anticancer treatment within 4 months or
radiotherapy within 3 weeks of initiation of sorafenib, and
prior or current use of type 1A or 3 antiarrhythmics,
anthracyclines, or anti-VEGF agents (including bev-
acizumab). Active CAD or MI B6 months prior to study
entry were allowed as long as LVEF was C45% at base-
line. Patients were treated with oral sorafenib 400 mg bid
until progressive disease (PD) or intolerance to the drug.
Although treatment was continuous, 28 days (4 weeks) of
treatment was deﬁned as 1 cycle. At the baseline visit
occurring 2 days before the start of cycle 1, assessments for
QT/QTc interval, BP, HR, and PK were performed. All
patients were required to be on a steady state of sorafenib
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diovascular safety parameters. The primary cardiovascular
outcome measures were LVEF, QT/QTc interval, BP, and
HR following continuous sorafenib monotherapy (refer to
Table 1 for study design details).
LVEF measure
LVEF was assessed by multigated acquisition (MUGA)
scan at baseline, after 2 and 4 cycles of sorafenib (day 1 of
cycles 3 and 5, respectively), and at study discontinuation.
The timing for LVEF measurements is consistent with the
median time to onset of CAEs reported in studies with
TKIs (8–16 weeks) [4, 7, 9].
QT/QTc interval measure
Cardiac repolarization was measured as the time from the
beginning of the Q-wave to the point where the T-wave
returns to the isoelectric point (QT/QTc interval) on an
electrocardiograph (ECG). The effect of steady state
exposure to sorafenib on cardiac repolarization was mea-
sured in triplicate, at baseline, and after 1 cycle of
sorafenib (day 1 of cycle 2). Measurements were recorded
before taking sorafenib, and 2, 4, 6, 8, and 12 h post-
sorafenib administration using continuous ECG monitoring
with a Mortara H-12 Plus, 12-Lead Digital Holter Recorder
(Mortara Instrument, Milwaukee, WI, USA) [21]. The
patients were in a supine position for 10 min prior to each
time point. The ECGs were transmitted via graphic ﬂash
cards from the investigation sites to eResearch Technology
(eRT, Philadelphia, PA, USA), which performed manual
ECG measurements. At the baseline visit occurring 1 day
before the start of cycle 1, QT/QTc intervals were also
measured (in triplicate) for moxiﬂoxacin oral 400-mg sin-
gle dose as a positive control. Moxiﬂoxacin, which pro-
duces a small (5–10 ms) increase in QT/QTc interval [22],
was used to demonstrate the ability of the study to pick up
this magnitude of effect. Measurements were recorded at
baseline prior to moxiﬂoxacin and 2 h post-moxiﬂoxacin
administration.
Blood pressure and heart rate measure
Supine BP and HR were recorded in duplicate, 1 min apart,
at baseline and after 1 and 4 cycles of sorafenib (on day 1
of cycles 2 and 5, respectively). Measurements were
recorded before patients received sorafenib, and 2, 4, 6, 8,
and12 hpost-sorafenibadministrationusingtheOmron907
Automated Blood Pressure Device (Omron, Bannockburn,
IL, USA).
Pharmacokinetic measure
Quantitative analysis of sorafenib and its metabolites
(BAY 43-9007, BAY 67-3472, BAY 68-7769) was
Table 1 Study design and procedure schedule
Treatment Screening Baseline Day 1 of cycle End
a
-2 days placebo -1 day mox
b 123456C7
Sorafenib 400 mg bid
Cardiovascular evaluations
LVEF, MUGA scan XX X X
QT interval, ECG
c,d XX
e X
Supine BP/HR
c,f XX X X
Other evaluations
PK X
g XX
Safety X X XXXXXX X
Efﬁcacy X X X X X
LVEF left ventricular ejection fraction, MUGA multigated acquisition scan, ECG electrocardiograph, BP blood pressure, HR heart rate, PK
pharmacokinetics
a End of treatment visit
b Moxiﬂoxacin (QT positive control) 400 mg
c Pre-dose, 2, 4, 6, 8, 12 h post-dose
d Patients were in supine position for 10 min prior to measurement. Measurements were taken in triplicate
e Pre-dose, 0.5, 1, 2, 3, 4 h post-dose
f Patients were in supine position for 5 min prior to measurement. Measurements were taken in duplicate; if the measurements differed by
C10 mm Hg, a third BP measurement was taken, and the mean of the 3 measurements was calculated
g Pre-dose only
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described previously [23]. Patients were included in the PK
analyses if they had plasma PK samples collected at
baseline and after 1 cycle and/or 4 cycles of sorafenib (on
day 1 of cycles 2 and/or 5, respectively). Blood samples for
PK analyses were collected from patients after supine
BP/HR measurements at the following time points: before
taking sorafenib, and 2, 4, 6, 8, and 12 h post-sorafenib
administration. PK analyses included area under the plasma
concentration versus time curve from time 0 to 12 h
(AUC(0–12)), maximum plasma concentration (Cmax), tmax,
and pre-dose plasma concentration (Ctrough,steady state).
Safety and efﬁcacy measures
General safety evaluation (including laboratory safety) was
carried out at screening, baseline, and on the ﬁrst day of
every cycle. The incidence, severity, and relationship of
AEs to study drug were recorded using the National Cancer
Institute-Common Terminology Criteria for Adverse
Events (NCI-CTCAE) v3.0. Tumor measurements were
performed at screening and after every 2 cycles while
patients were receiving sorafenib. Tumor response was
reviewed locally at each center using Response Evaluation
Criteria in Solid Tumors (RECIST). Documented approval
from the appropriate ethics committee(s)/institutional
review board(s) was obtained for all participating centers/
countries prior to study initiation. Written informed con-
sent was obtained from all patients.
Statistical analyses
The primary focus of this phase I study was to evaluate the
effect of chronic sorafenib administration on cardiovascu-
lar safety parameters. To achieve the deﬁned sample size of
35 patients who completed 4 or more cycles of sorafenib
therapy, 53 patients were enrolled. The sample size was
determined based on similar clinical studies with other
compounds that evaluated changes from baseline in BP,
HR, and QT/QTc interval in advanced cancer patients, and
was considered appropriate for identifying and evaluating
clinically important changes in such cardiovascular
parameters. Statistical analyses of each cardiovascular
parameter summarized measurements for observed values
and changes from baseline in a descriptive fashion.
LVEF analysis
To be included in LVEF analysis, patients were required to
have a baseline LVEF value and at least 1 post-sorafenib
LVEF value. The ‘‘primary analysis group’’ consisted of all
treated patients who met the above criteria and received at
least 1 dose of sorafenib. In addition, a ‘‘secondary analysis
group’’ consisting of patients who had received 75% of all
sorafenib doses, had missed less than 3 sorafenib doses in
the week preceding the MUGA scan, and had not missed
any doses in the 2 days preceding the MUGA scan was
evaluated. Baseline value used for change from baseline
calculation was deﬁned as the pre-dose value. Reported
values and changes from baseline were summarized in a
descriptive fashion.
QT/QTc interval analysis
For patients to be valid for QT/QTc analysis, they had to
receive sorafenib treatment and have at a minimum 1 set of
triplicate baseline ECG data and 1 set of triplicate post-
sorafenib ECG data. The primary analysis of the effect of
sorafenib on QT/QTc was the change in QT/QTc interval
from baseline at the maximum concentration of sorafenib
(tmax). Baseline was deﬁned as the QT/QTc measurements
recorded on the placebo dosing day at the same time as tmax
based on sorafenib plasma concentrations post-baseline.
Secondary analyses included the change in QT/QTc inter-
val from baseline over a 12-h period where baseline was
the corresponding measurement at the same time point on
the placebo dosing day, and the maximal change from
baseline over the 12-h period where baseline was the cor-
responding measurement at the same time point on the
placebo dosing day when tmax was observed post-baseline.
Reported values and changes from baseline were summa-
rized in a descriptive fashion. Changes in QT/QTc interval
caused by moxiﬂoxacin were evaluated from baseline by
time point where baseline was the corresponding mea-
surement at the same time point on the placebo dosing day.
For QTc evaluation, Fridericia’s correction formula
(QTcF = QT/RR
1/3) was used to correct for HR, where
RR = 60/HR. Bazett’s correction formula (QTcB = QT/
RR
1/2) was also used.
Blood pressure and heart rate analysis
For patients to be valid for BP and HR analyses, they had
to receive sorafenib treatment and have at minimum 1 set
each of duplicate baseline and duplicate post-sorafenib BP
and HR data. The primary analysis of the effect of
sorafenib on BP and HR was the change from baseline at
the maximum concentration (tmax) of sorafenib. Secondary
analyses included the change from baseline in BP/HR over
a 12-h period and the maximal change from baseline over
the 12-h period. Reported values and changes from base-
line were summarized in a descriptive fashion. Baseline
values for analyses evaluating change from baseline at tmax
of sorafenib by time point and maximal change were
similar to those deﬁned for other cardiovascular
parameters.
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The pharmacokinetic parameters were calculated using the
model-independent (compartment-free) method (WinNonlin,
PharsightCorporation,MountainView,CA,USA).Summary
statistics of plasma concentrations and derived pharmacoki-
netic variables at each sampling time were analyzed by time
point. Ratio of AUC and Cmax a td a y1o fc y c l e5t od a y1o f
cycle 2 were evaluated to determine the extent of accumula-
tion, if any.
Safety and efﬁcacy analyses
All patients who received at least 1 dose of sorafenib were
included in the safety analysis. Incidence rates of treat-
ment-emergent AEs, including relation to drug and seri-
ousness, were evaluated descriptively according to the
NCI-CTCAE v3.0. All patients who received C1 dose of
sorafenib were included in the efﬁcacy assessment. Patients
evaluable for objective overall tumor response required
disease to be re-evaluated (baseline and post-baseline
tumor evaluation) radiologically. Patients who discontin-
ued because of death or disease progression before the
tumor was re-evaluated were also evaluable. Descriptive
statistics summarized objective overall tumor response rate
(complete response [CR] and partial response [PR]) and
best response assessment using the RECIST criteria, and
descriptive Kaplan–Meier statistics were used to evaluate
efﬁcacy parameters such as PFS.
Results
Patient characteristics
Fifty-three patients were enrolled and treated in the study.
Patient baseline demographics are shown in Table 2. The
most common ﬁndings in the cardiovascular medical histo-
ries were hypertension (n = 25; 47.2%), tachycardia
(n = 5; 9.4%), MI (n = 3; 5.7%), and CAD (n = 2; 3.8%).
Most of the patients with a history of hypertension (22 of 25
patients) were taking antihypertensive medications at study
entry. The number of patients who met the criteria for
inclusion in the LVEF analysis was 32; QT/QTc interval
analysis,36;BPandHRanalysis,39;PKanalysis,27;safety
and efﬁcacy analysis, 53; and those evaluable for response,
47.Thedatabaseusedforallanalyseswasbasedonprotocol-
deﬁned analyses of the cardiovascular safety parameters.
LVEF results
Mean (SD) baseline LVEF(%) was 64.9 (7.0) in the pri-
mary patient group (n = 32; those who received C1 dose
Table 2 Patient baseline demographics, disease, and cardiovascular
characteristics
Sorafenib 400 mg bid
(N = 53)
Demographic baseline characteristics
Race, n (%)
Caucasian 48 (91)
Hispanic 5 (9)
Sex, n (%)
Female 21 (40)
Male 32 (60)
Mean age, y (SD) 56.8 (10.7)
\65 years, n (%) 41 (77)
C65 years, n (%) 12 (23)
Performance status (ECOG), n (%)
0 17 (32)
1 33 (62)
2 3 (6)
Cardiovascular risk assessment
Body mass index,
a mean (SD) 26.6 (5.5)
Obesity, n (%) 4 (8)
Diabetes mellitus, n (%) 5 (9)
Type 2 diabetes, n (%) 2 (4)
Hypercholesterolemia, n (%) 9 (17)
Hyperlipidemia, n (%) 4 (8)
Baseline disease characteristics
Stage IV/IVb at study entry, n (%) 53 (100)
Tumor type, n (%)
Renal cell carcinoma 11 (21)
Squamous cell carcinoma 5 (9)
Papillary carcinoma (thyroid) 3 (6)
Duct cell adenocarcinoma 2 (4)
Mesothelioma 2 (4)
Bone sarcoma 2 (4)
Non–small cell lung carcinoma 2 (4)
Prostate 1 (2)
Other, including unknown primary 26 (47)
Cardiovascular medical history, n (%)
Hypertension 25 (47)
Tachycardia 5 (9)
Myocardial infarction 3 (6)
Coronary artery disease 2 (4)
Mitral valve prolapse 2 (4)
Arrhythmia 1 (2)
Congestive heart failure 1 (2)
Left atrial dilatation 1 (2)
n = 32
Baseline cardiovascular characteristics
(at estimated tmax where indicated)
LVEF(%) (primary analysis group), mean (SD) 64.9 (7.0)
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123of sorafenib) and 65.58 (6.9) in the secondary patient group
(n = 25; those who received at least 75% of all required
doses of sorafenib). A minimal mean decline of 1.0 in
LVEF(%) occurred in both the primary patient group
(n = 31) and the secondary patient group (n = 25) after 2
cycles of treatment (Table 3). After 4 cycles of sorafenib,
mean declines of 1.2 and 1.4 in LVEF(%) occurred in the
primary (n = 24) and secondary (n = 14) patient groups,
respectively. In the primary group, a decrease from base-
line of C10 LVEF(%) was seen in 4 patients (12.9%) after
2 cycles, and in 1 patient (4.3%) after 4 cycles of sorafenib
(Fig. 1). In the secondary group, a decrease from baseline
of C10 LVEF(%) was found in 3 patients (12.0%) after 2
cycles, and in 1 patient (7.1%) after 4 cycles of sorafenib.
These 4 patients all had multiple concurrent illnesses that
may have contributed to the LVEF decreases (Table 4).
The largest individual decrease in ejection fraction (-24.8
LVEF[%]) was recorded in a patient who did not demon-
strate clinical signs of CHF. Overall 2 patients (6.5%)
experienced a post-baseline shift to B50 LVEF(%), the
above-mentioned patient and another patient after receiv-
ing 4 cycles of sorafenib; both of these patients are inclu-
ded in Table 4.
QT/QTc interval results
In 31 patients included in the primary QT/QTc analysis
after 1 cycle of sorafenib treatment, mean increases from
baseline of 9.0 and 4.2 ms were observed for QTcF and
QTcB, respectively, at the tmax of sorafenib, indicating a
modest prolongation of the QT/QTc interval. No patient
was observed to have a QTcB or QTcF value[500 ms at
any time during the study, and no patient showed a C60-ms
change from baseline in QTcB or QTcF. The maximum
prolongation in either QTcB or QTcF was a ?50 ms
change from QTcF baseline at tmax in 1 patient with an
adenocarcinoma of unknown primary origin. The baseline
QTcF for this patient was 396.7 ms, and after 1 cycle of
sorafenib treatment the value was 446.3 ms. For the sec-
ondary analyses, the mean increases from baseline by time
point ranged from 0.2 to 2.9 and 4.2 to 5.8 ms for QTcB
and QTcF, respectively, again indicating a modest QT
prolongation following continuous sorafenib treatment.
The mean maximal increases from baseline were 16.4 and
19.8 ms for QTcB and QTcF, respectively. All QT/QTc
results are shown in Table 5.
Blood pressure and heart rate results
Forthe primaryanalysis,mean(SD)increases frombaseline
in supine systolic and diastolic BP of 11.7 (±19.0) and 11.0
(±12.3) mm Hg, respectively, were observed at the tmax of
sorafenibafter 1cycle oftreatment (n = 31). Similar results
were seen after 4 cycles in the 16 patients evaluable for BP
(Table 3). In most patients, the BP values at each time point
measure did not exceed 150/90 mm Hg. Four patients
exceeded 150/90 mm Hg, another 4 patients exceeded a
systolic reading of 150 mm Hg, and another 2 patients had a
diastolic reading surpassing 90 mm Hg after 1 cycle of
sorafenib. After receiving 4 cycles of sorafenib only 2
patientsexceeded150/90 mmHg.After1cycleofsorafenib,
the secondary analyses of mean increases from baseline in
supine BP by time point showed that the largest mean
increase(15.9and12.2 mmHgforsystolicanddiastolicBP,
respectively)occurredat12 hpost-sorafenibadministration.
The mean (SD) maximal increases from baseline for supine
systolic and diastolic BP were 27.7 (±18.5) and 19.8 (±9.0)
mm Hg, respectively, after 1 cycle of sorafenib. Compen-
satorymeanchangesfrombaselineinsupineHRof-6.6and
-3.3 bpm were reported after 1 and 4 cycles of sorafenib in
30 and 13 evaluable patients, respectively. In secondary
analyses, mean changes from baseline in supine HR by time
point showed that after 1 cycle of sorafenib the largest mean
change (-6.0 bpm) occurred 6 h post-sorafenib adminis-
tration. Mean (SD) maximal decreases from baseline in
supine HR of 2.9 (±8.2) bpm and 8.3 (±6.8) bpm were
reportedafter1and4cyclesofsorafenib,respectively.Three
patients started receiving antihypertensive medications
during treatment with sorafenib.
Pharmacokinetic results
The PK data from this study are consistent with previous
ﬁndings at the steady state of sorafenib in patients with
cancer receiving sorafenib 400 mg bid (Table 6). After 1
Table 2 continued
n = 32
Systolic BP at tmax,
b mm Hg, mean (SD) 123.5 (23.0)
Diastolic BP at tmax,
b mm Hg, mean (SD) 68.4 (13.3)
HR at tmax,
b bpm, mean (SD) 81.0 (16.5)
n = 31
QT/QTc at tmax,
b ms, mean (SD)
QT 378.5 (39.3)
QTcB 437.6 (16.4)
QTcF 416.5 (20.3)
SD standard deviation, ECOG Eastern cooperative oncology group,
BP blood pressure, HR heart rate, bpm beats per minute, LVEF left
ventricular ejection fraction, QTcF Fridericia’s-corrected QT interval,
QTcB Bazett’s-corrected QT interval
a Mean body mass index was based on 52 patients
b Measurements from placebo dosing day at corresponding time point
of tmax post-baseline
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LVEF(%) Sorafenib 400 mg bid
n Mean (SD) change from baseline n Mean (SD) change from baseline
Day 1 of cycle 3 Day 1 of cycle 5
Change from baseline
Primary analysis population 31 -0.8 (8.6) 24 -1.2 (7.8)
Secondary analysis population 25 -1.0 (8.5) 14 -1.4 (9.4)
BP/HR Day 1 of cycle 2 Day 1 of cycle 5
C150/90 mm Hg at tmax, n (%) 31 10
a (32) 16 2
b (13)
Primary BP/HR analysis (mm Hg/bpm)
Change from baseline at tmax
c
Supine systolic BP 31 11.7 (19.0) 16 11.1 (11.8)
Supine diastolic BP 31 11.0 (12.3) 16 11.9 (13.6)
Supine HR 30 -6.6 (10.6) 13 -3.3 (7.3)
Secondary BP/HR analyses (mm Hg/bpm)
Change from baseline over time
d
Supine systolic BP
Pre-dose
e 34 9.1 (18.9) 19 13.4 (13.9)
2 h 35 8.2 (19.8) 19 13.3 (18.6)
4 h 34 11.7 (20.8) 18 11.0 (18.1)
6 h 35 13.8 (20.4) 19 15.4 (15.7)
8 h 34 14.8 (20.8) 19 12.4 (15.4)
12 h 34 15.9 (18.8) 18 12.9 (16.0)
Supine diastolic BP
Pre-dose
e 34 7.6 (14.0) 19 11.1 (12.8)
2 h 35 7.4 (11.5) 19 11.4 (13.1)
4 h 34 10.8 (11.6) 18 11.8 (13.2)
6 h 35 11.3 (13.0) 19 13.6 (11.4)
8 h 34 11.0 (12.4) 19 14.4 (13.5)
12 h 34 12.2 (9.7) 18 9.1 (12.0)
Supine HR
Pre-dose
e 33 -4.4 (8.1) 16 -2.9 (10.0)
2h 3 5 -5.4 (9.2) 16 -0.03 (7.1)
4h 3 4 -4.0 (8.8) 16 0.1 (9.2)
6h 3 5 -6.0 (8.9) 16 0 (8.7)
8h 3 4 -4.2 (11.3) 16 0.7 (8.6)
12 h 34 -5.8 (13.3) 15 1.6 (10.0)
Maximal change from baseline
f
Supine systolic BP 35 27.7 (18.5) 19 24.8 (14.4)
Supine diastolic BP 35 19.8 (9.0) 19 22.0 (11.2)
Supine HR 35 2.9 (8.2) 16 8.3 (6.8)
LVEF left ventricular ejection fraction, SD standard deviation, BP blood pressure, HR heart rate, bpm beats per minute
a Four patients had both systolic and diastolic C150/90 mm Hg, 4 patients had only systolic C150 mm Hg, 2 patients had only diastolic C90 mm
Hg
b Two patients exceeded only diastolic C90 mm Hg
c Measurements from placebo dosing day at corresponding time point of tmax post-baseline were used as the baseline values for analysis
d Measurements from placebo dosing day at each corresponding time point post-baseline were used as the baseline values for analysis
e Pre-dose: Measurements taken before the administration of placebo (baseline) or sorafenib (on day 1 of cycle 2)
f Measurements from placebo dosing day at corresponding time point maximum value observed post-baseline were used as the baseline values
for analysis
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123cycle of sorafenib, the AUC(0–12) geometric mean (% CV)
was 42.8 mg h/L (36.1%) and the Cmax geometric mean (%
CV) was 5.4 mg/L (53.2%). A general trend toward a
decrease in both AUC(0–12) and Cmax of sorafenib occurred
in patients receiving more than 1 cycle of treatment. This
trend was stronger for all of the metabolites than for so-
rafenib. The observed decrease may be due to an unre-
ported lack of adherence, a common issue with oral
medications. The relationship between PK parameters
(AUC(0–12), Cmax) and cardiovascular safety parameters
(QT/QTc, LVEF, BP, and HR) was explored by correlating
PK parameters after 1 cycle of sorafenib to QT/QTc
interval and BP and HR after 1 cycle and to LVEF after 2
cycles of sorafenib. An additional analysis was performed
to evaluate the correlation of PK parameters with LVEF,
BP, and HR following 4 cycles of sorafenib. No relation-
ship was observed between any of the PK parameters and
the cardiovascular safety parameters at any time point (data
not shown).
Safety and efﬁcacy results
Median daily dose in the 53 patients valid for the safety
analysis was 800 mg of sorafenib (range 133–800 mg).
The median duration of treatment was 16 weeks (range
1–128 weeks) with 14 (26.4%) patients receiving sorafenib
for longer than 24 weeks and 6 (11%) patients longer than
50 weeks. Treatment interruptions and dose reductions
occurred in 40 (75.5%) and 23 (43.4%) patients, respec-
tively, with treatment-emergent AEs being the reason for
treatment interruptions in 23 (43.4%) patients and for dose
reductions in 17 (32.1%) patients. Drug-related treatment-
emergent AEs were reported in 43 (81%) patients, and
drug-related treatment-emergent AEs C grade 3 were
reported in 16 (30%) patients (Table 7). The most common
drug-related treatment-emergent AEs were rash/desqua-
mation, hand-foot skin reaction (HFSR), and diarrhea. Two
(4%) patients reported drug-related treatment-emergent
serious AEs (SAEs). One patient with metastatic RCC, a
history of breast cancer, hypertension (managed with an
oral calcium-channel blocker), heart attack, and right
internal carotid stenosis experienced a complete atrioven-
tricular block (grade 3) that promptly resolved upon
implantation of a permanent dual chamber pacemaker. One
patient with advanced mesothelioma and an extensive
cardiovascular medical history (CAD status post–left heart
catheterization and CHF, MI, angioplasty, angina pectoris,
and hypertension managed with a beta blocker) had grade 4
central nervous system (CNS) ischemia. One patient with
thymic carcinoma and a baseline LVEF value of 72%
reported CHF that was clearly secondary to a pulmonary
embolism (PE) and considered by the investigator to be
unrelated to sorafenib treatment. Other AEs that this
patient reported during the CHF episode were grade 2
dyspnea on exertion, grade 2 atrial ﬂutter (AFl), grade 2
pleural effusion, and grade 1 hypotension. LVEF by
echocardiogram (ECHO) was measured as 25% during the
hospital conﬁnement. However, this value is confounded
by the use of ECHO instead of MUGA scan and the
presence of PE and AFl. Upon aggressive treatment for the
AFl and PE, the LVEF value returned to normal (60–65%),
and the patient resumed treatment with sorafenib without
further signiﬁcant AEs. Seven patients discontinued from
the study because of AEs, 3 of which were drug-related,
including 1 patient with grade 3 HFSR, 1 patient with
grade 3 scalp rash, and the 1 patient with the grade 3
atrioventricular block. Seven deaths were reported during
the study or within 30 days of the last dose; all were sec-
ondary to disease progression and considered unrelated to
study drug.
Data used for efﬁcacy analyses were based on protocol-
deﬁned analyses of the cardiovascular safety parameters.
Of the 48 (91%) patients evaluable for tumor response, 1
(2.1%) female patient with mesothelioma achieved a PR,
31 (65%) patients had stable disease, and 13 (27%) patients
had PD as best response. For the intent to treat (ITT)
population (n = 53), median overall survival was not
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123estimable due to censored data; 46 (87%) patients were
alive (censored) and 7 (13%) patients had died by the time
of analysis. The median PFS was 4.1 months (95% CI 2.8–
6.4 months).
Discussion
This cardiovascular safety trial of sorafenib in 53 patients
with advanced cancer assessed the effect of sorafenib on
various cardiovascular parameters. There was little evi-
dence of an overall decrement in ejection fraction from
baseline in patients with cancer treated with sorafenib
400 mg bid; however, both increases and decreases were
observed in LVEF, and isolated patients had a C10
LVEF(%) decrease in ejection fraction, as measured by
serial MUGA scans. These modest changes in LVEF would
not be entirely unexpected in a population of patients with
metastatic cancer whose overall health is generally dete-
riorating over time.
This study should be put in context with other studies of
multitargeted kinase inhibitors of VEGFR. Several studies
have reported an association between sunitinib, another
multitargeted TKI, and heart failure and/or a C10
LVEF(%) reduction [1, 4–10]. An observational study by
Schmidinger et al. analyzed patients who had received
treatment with antiangiogenic therapy (either sunitinib or
sorafenib) in their clinic. The incidence of C10 LVEF(%)
reduction was 14% in patients receiving sunitinib and 5%
in patients receiving sorafenib [4, 24]. Similar results were
seen in our detailed cardiovascular study, with a C10
LVEF(%) reduction reported in 13% of patients after 2
cycles of sorafenib and in 4% of patients after 4 cycles of
sorafenib. In the study by Chu et al. the mean change after
2 and 4 cycles of sunitinib was -2.2 LVEF(%) and -5.1
LVEF(%), respectively [5], compared with the results in
this study of -0.8 and -1.2 seen after 2 and 4 cycles of
sorafenib. In light of this, it is also encouraging to ﬁnd that
in this phase I study of sorafenib, the number of patients
receiving sorafenib treatment who had a C10% LVEF(%)
reduction was low, but a direct comparison without a
randomized study is not possible. A recent study by Hutson
et al. reported declines to\50 LVEF(%) in 12% of patients
after 1 cycle (6 weeks), 10% of patients after 1 year, and
5% of patients after 2 years of sunitinib, suggesting a
minimal cumulative effect on LVEF with long-term treat-
ment with an antiangiogenic TKI [10].
Delays in cardiac repolarization after treatment can lead
to arrhythmias such as torsades de pointes (TdP) or other
ventricular tachyarrhythmias that can result in ventricular
ﬁbrillation and, occasionally, sudden death [25]. There is
increasing regulatory scrutiny of the effects of novel
Table 5 Changes in QT/QTc interval after 1 cycle of sorafenib treatment (on day 1 of cycle 2)
Sorafenib 400 mg bid
Mean (SD) change from baseline
n QT (ms) QTcB (ms) QTcF (ms)
Day 1 of cycle 2
Primary ECG analysis
Change from baseline at tmax
a 31 17.4 (29.3) 4.2 (19.2) 9.0 (18.0)
Secondary ECG analyses
Change from baseline over time
b
Pre-dose
c 34 12.3 (26.6) 1.1 (18.3) 5.2 (18.3)
2 h 35 10.6 (27.8) 0.5 (18.0) 4.2 (17.9)
4 h 35 10.7 (29.4) 2.0 (20.2) 5.2 (19.4)
6 h 35 13.1 (27.0) 1.6 (17.3) 5.7(18.1)
8 h 35 12.2 (27.3) 0.2 (16.1) 4.5 (14.4)
12 h 31 10.6 (29.6) 2.9 (17.2) 5.8 (19.1)
Maximal change from baseline
d 36 32.9 (24.1) 16.4 (15.3) 19.8 (14.4)
Moxiﬂoxacin (positive control)
Change from baseline at 2 h post-dose
b 49 5.7 (24.3) 4.4 (12.9) 4.9 (13.7)
ECG electrocardiograph, SD standard deviation, QTcF Fridericia’s-corrected QT interval, QTcB Bazett’s-corrected QT interval
a Measurements from placebo dosing day at corresponding time point of tmax post-baseline were used as the baseline values for analysis
b Measurements from placebo dosing day at each corresponding time point post-baseline were used as the baseline values for analysis
c Pre-dose: Measurements taken before the administration of placebo (baseline) or sorafenib (on day 1 of cycle 2)
d Measurements from placebo dosing day at corresponding time point maximum value observed post-baseline were used as the baseline values
for analysis
760 Cancer Chemother Pharmacol (2011) 67:751–764
123oncology drugs on cardiac repolarization to assess the
potential for life-threatening arrhythmias [26]. This is the
ﬁrst full in-depth analysis of the effect of sorafenib treat-
ment on QT/QTc interval prolongation. Moxiﬂoxacin, a
quinolone antibiotic, was selected as the positive control in
this study because it has a well-documented ability to
prolong cardiac repolarization [22]. The QT/QTc interval
prolongation observed with moxiﬂoxacin in this study was
within the range of those reported in other studies [27, 28],
indicating that the methodology used was sensitive enough
to detect small changes in the QT/QTc interval. Because
increases in the risk of arrhythmias correlate with the
extent of QT/QTc interval prolongation, drugs that prolong
the mean QT/QTc interval by B5 ms are generally con-
sidered to cause no relevant QTc prolongation. In this
study, the mean maximal increases from baseline (QTcB:
16 ms; QTcF: 20 ms) indicate that sporadic QT/QTc
interval prolongation up to these values can occur
Table 6 Pharmacokinetic parameters in plasma at steady state of sorafenib
Geometric mean (% CV) Sorafenib 400 mg bid
Day 1 of cycle 2
(n = 17)
a
Day 1 of cycle 5
(n = 17)
a
Ratio
b (90% CI)
(n = 17)
a
Sorafenib
AUC, mg h/L 42.8 (36.1) 36.0 (58.2) 0.84 (0.69–1.02)
AUCnorm, kg h/L 7.5 (48.4) 6.3 (69.8)
Cmax, mg/L 5.4 (53.2) 4.3 (62.1) 0.79 (0.66–0.94)
Cmax,norm, kg/L 1.0 (64.9) 0.8 (72.5)
Ctrough, mg/L 4.1 (73.6) 3.2 (73.8) 0.78 (0.61–0.99)
Ctrough,norm, kg/L 0.7 (85.4) 0.6 (83.8)
tmax, h, median (range) 2.00 (0–12.00) 2.00 (0–8.05)
N-demethyl metabolite (BAY 43-9007)
AUC, mg h/L 2.0 (59.1) 1.1 (74.0) 0.57 (0.41–0.81)
AUCnorm, kg h/L 0.4 (62.8) 0.2 (80.9)
Cmax, mg/L 0.2 (73.4) 0.1 (75.5) 0.51 (0.38–0.68)
Cmax,norm, kg/L 0.1 (75.2) \0.1 (78.2)
Ctrough, mg/L 0.2 (82.3) 0.1 (82.4) 0.52 (0.38–0.70)
Ctrough, norm, kg/L \0.1 (85.0) \0.1 (84.8)
tmax, h, median (range) 1.00 (0–12.00) 2.00 (0–12.00)
N-oxide metabolite (BAY 67-3472)
AUC, mg h/L 8.5 (58.3) 5.2 (98.7) 0.61 (0.41–0.92)
AUCnorm, kg h/L 1.4 (59.6) 0.9 (103.2)
Cmax, mg/L 1.0 (66.8) 0.6 (96.9) 0.58 (0.41–0.82)
Cmax,norm, kg/L 0.2 (70.2) 0.1 (100.7)
Ctrough, mg/L 0.8 (81.1) 0.5 (109.4) 0.54 (0.36–0.81)
Ctrough, norm, kg/L 0.1 (85.9) 0.1 (111.5)
tmax, h, median (range) 1.00 (0–12.00) 2.00 (0–8.12)
N-oxide metabolite of BAY 43-9007 metabolite (BAY 68-7769)
AUC, mg h/L 2.8 (92.3) 1.4 (129.3) 0.50 (0.28–0.89)
AUCnorm, kg h/L 0.5 (91.4) 0.3 (128.1)
Cmax, mg/L 0.3 (101.6) 0.2 (127.2) 0.47 (0.28–0.80)
Cmax,norm, kg/L 0.1 (99.6) \0.1 (123.6)
Ctrough, mg/L 0.3 (114.5) 0.1 (127.8) 0.49 (0.29–0.83)
Ctrough, norm, kg/L 0.1 (113.5) \0.1 (124.7)
tmax, h, median (range) 2.00 (0–12.00) 2.00 (0–8.05)
AUC area under the curve, CI conﬁdence interval, CV coefﬁcient of variation, Cmax maximum concentration, Ctrough trough concentration, tmax
time to maximum concentration
a n = 14 for area under the curve (AUC) analysis
b Ratio of day 1 of cycle 5 versus day 1 of cycle 2
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123following continuous treatment with sorafenib. However,
in the absence of a placebo group and a crossover design, it
was not possible to deﬁne the maximal effect on QT/QTc
interval prolongation occurring in the sorafenib-treated
population with advanced cancer in this study. For this
reason, increases from baseline of 9 and 4 ms observed for
QTcF and QTcB, respectively, at the tmax of sorafenib are
the best estimate of the effect of sorafenib on QTc pro-
longation, and based on the results of this detailed QT
study, demonstrate the absence of a likely clinically rele-
vant effect of sorafenib at therapeutic (400 mg bid) doses
on cardiac repolarization. In a recent evaluation of the
effects of sunitinib on the QT/QTc interval of 24 patients
with advanced cancer with a similar baseline QTcF
(411.8 ms), the maximum placebo-adjusted, time-matched
QTcF and QTcB prolongations at 24 h post-sunitinib
(50 mg daily) on the third day of treatment were 9.6 (90%
CI 4.1–15.1) and 7.9 ms (90% CI 3.0–12.8), respectively
[28]. In the study there was an increase in QTcF prolon-
gation with increasing total drug concentrations.
The direct effect of sorafenib on mean change from
baseline in BP at the tmax of sorafenib was similar after
both 1 and 4 cycles of sorafenib treatment. Both the sys-
tolic and diastolic BP increased *11–12 mm Hg at both
time points, indicating a deﬁnite but modest increase in BP
with sorafenib. Thirty-two percent of patients had become
hypertensive after 1 cycle of treatment with sorafenib, up
from 6% at baseline. However, the rate dropped to 13% of
patients at cycle 4. This may be due to the physiologic
increase in vascular tension resulting from VEGF inhibi-
tion, or more likely, the increased use of antihypertensive
medication to control the treatment-emergent hypertension.
There were minimal decreases in HR following 1 cycle of
sorafenib, which normalized after 4 cycles. The moderate
changes observed in BP and HR are consistent with
expectations for agents that inhibit signaling through the
VEGF pathway.
By inhibiting angiogenesis, therapies that target VEGF
(i.e., sorafenib, sunitinib, bevacizumab) increase hyper-
tension in patients [29–32] and may increase the incidence
of CAEs due to pleiotropic effects on the vasculature and
cardiac tissues. The prevalence of hypertension with the
use of antiangiogenic agents is so common that elevation in
BP during treatment has been proposed as a candidate
biomarker for VEGF inhibition [33–38]. Of note, the
patient with the best tumor response to sorafenib in this
study (conﬁrmed PR) had the highest mean increase from
baseline in both systolic and diastolic BP after both 1 and 4
cycles of sorafenib (systolic BP: 44.5 and 29.3 mm Hg,
respectively, and diastolic BP: 31.0 and 40.8 mm Hg,
respectively). However, although the incidence of hyper-
tension after treatment with agents that inhibit VEGF has
been well established, it should still be adequately treated
and carefully monitored [24, 39]. Early recognition and
proactive management of hypertension are important to
avoid poorly controlled hypertension that can lead to
serious CAEs.
AUC(0–12) and Cmax were similar in this study for
sorafenib and its metabolites (BAY 43-9007, BAY
67-3472, BAY 68-7769) to results from previous studies in
patients with cancer [23, 40, 41]. There was no apparent
relationship between mean plasma exposure and cardio-
toxicity. A small decrease in AUC(0–12) and Cmax from 1
cycle to 4 cycles of treatment was seen for sorafenib and its
3 metabolites. Although the reason for this decrease in
exposure is not known, the time course of the effect sug-
gests that an induction of metabolism is an unlikely cause.
Lack of compliance may be a contributing reason for the
decreasing trend in mean plasma concentration of sorafenib
and its metabolites after 3 cycles of treatment.
Although this study reported modest cardiovascular
effects of continuous sorafenib in patients with advanced
cancer, the difﬁculty of carrying out this study in healthy
volunteers precludes a broader deﬁnition of the cardio-
vascular proﬁle of sorafenib. In addition, obtaining precise
cardiovascular evaluations of sorafenib in the setting of a
population with advanced cancer is limited by ethical and
other medical considerations, including the absence of a
placebo group, the difﬁculty in evaluating patients for the
duration of a study with a crossover design, as is often done
in healthy volunteer QT studies, multiple comorbidities and
changes in the physiological status of cancer patients over
time, and the inability to restrict the use of concomitant
medications by the patients.
The successful management of treatment-emergent
cardiac comorbidities and asymptomatic signs of
Table 7 Drug-related treatment-emergent adverse events occurring
in C10% of patients (all grades)
Number of patients (N = 53)
All grades n (%) Grade C3 n (%)
Any drug-related adverse event 43 (81) 16 (30)
Rash/desquamation 20 (38) 3 (6)
Hand-foot skin reaction 16 (30) 6 (11)
Diarrhea 15 (28) 1 (2)
Alopecia 13 (25) 0 (0)
Pain, extremity—limb 12 (23) 0 (0)
Mucositis 8 (15) 1 (2)
Fatigue 8 (15) 1 (2)
Nausea 7 (13) 0 (0)
Dermatology—other 7 (13) 1 (2)
Sensory neuropathy 7 (13) 0 (0)
Hypertension 6 (11) 1 (2)
Dermal change 6 (11) 0 (0)
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123cardiotoxicity is required to maximize the clinical beneﬁt
for patients with cancer being treated with antiangiogenic
agents [8, 24, 42, 43]. The reversibility of CAEs and the
effect of a CAE on a patient must be considered during
treatment with such therapies. When assessing whether a
patient should continue antiangiogenic treatment after a
CAE has resolved, the life-prolonging beneﬁt and
improvement in quality of life that antiangiogenic treat-
ment may offer to patients with advanced cancer must be
considered. In many instances, patients may be able to
continue treatment at a lower dose or switch to another
antiangiogenic therapy without incurring new cardiovas-
cular damage [4, 44]. However, additional studies are
needed to deﬁne the circumstances under which antian-
giogenic treatment may be undertaken without risking
cardiac damage in patients [45, 46].
Conclusion
This study was speciﬁcally designed to assess the cardio-
vascular effects of continuous sorafenib treatment in a
patient population with advanced cancer; however, the
results from these cardiovascular analyses should be
interpreted with caution due to the descriptive nature of the
study design and limited sample size. Overall, the effects of
continuous sorafenib on the cardiovascular parameters of
QTc interval and LVEF observed in the current study were
modest and unlikely to be of clinical signiﬁcance in the
setting of advanced cancer treatment. The effects of con-
tinuous sorafenib on BP and HR were moderate and con-
sistent with expectations based on experience with other
anti-VEGF targeting agents.
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